Imaging biomarkers in tauopathies

Parkinsonism and Related Disorders

Volumn 22, Issue , 2016, Pages S26-S28

  Dani, Melanie ^a   Edison, Paul ^a   Brooks, David J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Alzheimer; CBD; Dementia; PET; PSP; Tau imaging

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CARBON PBB 3 C 11; FLUORINE AV 1451 F 18; FLUORINE FDDNP F 18; FLUORINE T 808 F 18; FLUORINE THK 5117 F 18; FLUORINE THK 523 F 18; FLUORINE THK 5351 F 18; RADIOPHARMACEUTICAL AGENT; RO 6924963; RO 6931643; RO 6958948; TAU PROTEIN; UNCLASSIFIED DRUG;

AMYLOID NEUROPATHY; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TAUOPATHY; ALZHEIMER DISEASE; ANIMAL; BRAIN; METABOLISM; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLE; PATHOLOGY; PROCEDURES; SUPRANUCLEAR PALSY, PROGRESSIVE; TAUOPATHIES; TRENDS;

ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; BRAIN; HUMANS; MOLECULAR IMAGING; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES;

EID: 84947792785     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.08.011     Document Type: Article

References (29)

1. Ingelsson M.F., Newell K.L., Growdon W.H., et al. Early amyloid accumulation and progressive synaptic loss, gliosis and tangle formation in the Alzheimer's disease brain. Neurology 2004, 62:925-931.
2. Ittner L.M., Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
3. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann. Neurol. 1999, 45:358-368.
4. Barrio J.K., Satyamurthy N., Huang S., Small G. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J. Nutr. Health Ageing 2008, 12:61(S)-65(S).
5. Small G., Siddarth P., Kepe V., Ercoli L., et al. Prediction of cognitive decline by positron emissions tomography of brain amyloid and tau. Arch. Neurol. 2012, 69:215-220.
6. Fodero-Tavoletti M.O., Furomoto S., Mulligan R., et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
7. Harada R., Okamura N., Furumoto S., et al. [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2015, 42(7):1052-1061.
8. Nordberg A.C., Aubert L., Wall A., et al. Tau imaging with [18F]-(S)-THK5117 in MCI and AD patients using a PET multi-tracer concept. Hum. Amyloid Imaging 2015, ID 106.
9. Harada R., Okamura N., Furumoto S., et al. First-in-human PET study of a novel tau tracer [18F]THK-5351. Human Amyloid Imaging Conference 2015, ID 24.
10. Chien D.T., Szardenings A.K., Bahri S., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J. Alzheimer's Dis. 2014, 38:171-184.
11. Xia C.F., Arteaga J., Chen G., et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimer's Dement. 2013, 9:666-676.
12. Marquie M.N., Vanderburg C., Costantino, Dickerson B., et al. Towards the Validation of Novel PET Tracer T807 on Postmortem Human Brain Tissue Samples 2015, 28. Abstract Online: Human Amyloid Imaging 2015 Submission ID 89.
13. Chien D.T., Bahri S., Szardenings A.K., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimer's Dis. 2013, 34:457-468.
14. Pontecorvo M.D., Joshi A., Lu M., et al. Relationships between florbetapir PET amyloid and 18F AV-1451 (aka 18F-T807) PET tau binding in cognitively normal subjects and patients with cognitive impairments suspected of Alzheimer's disease. Hum. Amyloid Imaging 2015, ID 98.
15. Johnson K.B., Sepulcre J., Rentz D., et al. Tau PET: initial experience with F18 T807. Hum. Amyloid Imaging 2014, ID 103.
16. Mintun M.D., Pontecorvo M., Joshi A., et al. Potential for PET imaging tau tracer 18F-AV-1451 (also known as 18F-T807) to detect neurodegenerative progression in Alzheimer's disease. Hum. Amyloid Imaging 2015, ID 95.
17. Ossenkoppele R., Schonhaut D.R., Baker S.L., et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann. Neurol. 2015, 77:338-342.
18. Ossenkoppele R., Schonhaut D.R., Baker S.L., et al. Distinct [18F]AV1451 retention patterns in clinical variants of Alzheimer's disease. Hum. Amyloid Imaging 2015.
19. Gomperts S.M., Schultz A., Caso C., et al. [18F] T807 PET imaging of hyperphosphorylated tau to differentiate PSP from PD. Hum. Amyloid Imaging 2015, ID 118.
20. Dickerson B.M., Gomperts S., Caso C., et al. [18F]T807 of frontotemporal lobar degeneration. Hum. Amyloid Imaging 2015, ID 61.
21. Rabinovici G.D., Schonhaut D.R., Baker S.L., et al. Preliminary experience with [18F]AV1451 PET in non-AD neurodegenerative syndromes. Hum. Amyloid Imaging 2015.
22. Mitsis E.M., Riggio S., Kostakoglu L., et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Trans. psychiatry 2014, 4:e441.
23. Lockhart S.N., Vogel J.W., Schonhaut D.R., et al. Effects of age and β-amyloid on tau deposition measured using [18F] AV-1451 in normal older people. Hum. Amyloid Imaging 2015.
24. Schultz A.C., Mormino E., LaPoint M., Dagley A., Sperling R., Johnson K. Relationship between longitudinal amyloid accumulation and T807-tau. Hum. Amyloid Imaging 2015, ID 101.
25. Sperling R.M.E., Rentz D., Schultz A., et al. T807 PET measures of tau pathology associated with episodic memory performance among clinically normal older individuals. Hum. Amyloid Imaging 2015, ID 123.
26. Maruyama M., Shimada H., Suhara T., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013, 79:1094-1108.
27. Shimada H., Higuchi M., Ikoma Y., et al. In vivo visualization of tau pathology. Alzheimer's Dement. 2013, 9:P101-P102.
28. Shimada H., Shinotoh H., Sahara N., et al. Diagnostic utility and clinical significance of tau PET imaging with [11C]PBB3 in diverse tauopathies. Hum. Amyloid Imaging 2015, ID 69.
29. Honer M.K., Gobbi L., Kuwubara H., et al. In vitro and in vivo evaluation of RO6931643, RO6924963 and RO6958948 candidate PET tracers for aggregated tau. Hum. Amyloid Imaging 2015, ID 34.